Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
B Sousa-Pinto,R Louis,J M Anto,R Amaral,A Sá-Sousa,W Czarlewski,L Brussino,G W Canonica,C Chaves Loureiro,A A Cruz,B Gemicioglu,T Haahtela,M Kupczyk,V Kvedariene,D E Larenas-Linnemann,Y Okamoto,M Ollert,O Pfaar,N Pham-Thi,F Puggioni,F S Regateiro,J Romantowski,J Sastre,N Scichilone,L Taborda-Barata,M T Ventura,I Agache,A Bedbrook,S Becker,K C Bergmann,S Bosnic-Anticevich,M Bonini,L-P Boulet,G Brusselle,R Buhl,L Cecchi,D Charpin,F de Blay,S Del Giacco,J C Ivancevich,M Jutel,L Klimek,H Kraxner,P Kuna,D Laune,M Makela,M Morais-Almeida,R Nadif,M Niedoszytko,N G Papadopoulos,A Papi,V Patella,B Pétré,D Rivero Yeverino,C Robalo Cordeiro,N Roche,P W Rouadi,B Samolinski,M Savouré,M H Shamji,A Sheikh,C Suppli Ulrik,O S Usmani,A Valiulis,A Yorgancioglu,T Zuberbier,J A Fonseca,E M Costa,J Bousquet
DOI: https://doi.org/10.1016/j.pulmoe.2023.07.004
IF: 11.7
2023-08-03
Pulmonology
Abstract:Introduction: Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA. Materials and methods: We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day. Results: In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001). Conclusions: In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.